Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22999953 | 0.85 | KDM4E (0.72) | KDM4ETSHRRAB9ACA4CA6 | |
| SCHEMBL23000006 | 0.77 | KDM4E (0.62) | KDM4ETSHRRAB9ACA4CA6 | |
| SCHEMBL9176147 | 0.75 | TDP1 (0.65) | CA4CA6CA7CA9CA14 | |
| SCHEMBL3056859 | 0.74 | MAPT (0.74) | KDM4ETSHRRAB9ACA4CA6 | |
| Arsanilic Acid SCHEMBL4837583 | 0.72 | KDM4E (1.00) | KDM4ETSHRRAB9ACA4CA6 | |
| SCHEMBL11078484 | 0.72 | TSHR (0.56) | KDM4ETSHRRAB9ACA4CA6 | |
| SCHEMBL11034243 | 0.72 | TSHR (0.56) | KDM4ETSHRRAB9ACA4CA6 | |
| SCHEMBL20916723 | 0.72 | KDM4E (0.56) | KDM4ETSHRRAB9ACA4CA6 | |
| Arsanilic Acid SCHEMBL160507 | 0.72 | KDM4E (1.00) | KDM4ETSHRRAB9ACA4CA6 | |
| Phenylarsonic Acid SCHEMBL10784553 | 0.71 | CA4 (1.00) | KDM4ETSHRRAB9ACA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3676282-B1 | ANTI-CANCER AGENT | UNIV WOLLONGONG (AU) | 2024-11-06 | — | — | EP | disclosed |
| CN-111344298-B | Anticancer agent | 伍伦贡大学 | 2024-05-28 | — | — | CN | disclosed |
| US-11819489-B2 | Anti-cancer agent comprising a tumour homing peptide having arsenic bonded to cysteine residues | UNIVERSITY OF WOLLONGONG (AU) | 2023-11-21 | — | — | US | disclosed |
| US-20210205259-A1 | ANTI-CANCER AGENT | UNIVERSITY OF WOLLONGONG (AU) | 2021-07-08 | — | — | US | disclosed |
| EP-3676282-A1 | ANTI-CANCER AGENT | University of Wollongong (AU) | 2020-07-08 | — | — | EP | disclosed |
| CN-111344298-A | Anticancer agent | 伍伦贡大学 | 2020-06-26 | — | — | CN | disclosed |
| WO-2019075507-A9 | ANTI-CANCER AGENT | UNIVERSITY OF WOLLONGONG (AU) | 2020-05-22 | — | — | WO | disclosed |
| WO-2019075507-A1 | ANTI-CANCER AGENT | UNIVERSITY OF WOLLONGONG (AU) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205259-A1 | ANTI-CANCER AGENT | CCL2, CD44, CXCL12 | KDM4E 4367/4885TSHR 2233/4885RAB9A 1496/4885 |
| US-11819489-B2 | Anti-cancer agent comprising a tumour homing peptide having arsenic bonded to cysteine residues | CCL2, AS3MT, CXCL12 | KDM4E 4569/4885TSHR 2157/4885RAB9A 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.